REFERENCES
1. NCCN. NCCN clinical practice guidelines in oncology: non–small cell lung cancer, version 3. 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl_harmonized-vietnam.pdf [Last accessed on 20 Feb 2024].
2. The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association; China Primary Health Care Foundation Tumor Precision Diagnosis and Treatment Committee; Chinese Anti-Cancer Association, Lung Cancer Study Group of Committee of Oncopathology. [Chinese expert consensus on the clinical practice of non-small cell lung cancer fusion gene detection based on RNA-based NGS]. Zhongguo Fei Ai Za Zhi 2023;26:801-12.
3. Davies KD, Lomboy A, Lawrence CA, et al. DNA-based versus rna-based detection of MET exon 14 skipping events in lung cancer. J Thorac Oncol 2019;14:737-41.
4. Claerhout S, Lehnert S, Vander Borght S, et al. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer. Lung Cancer 2022;166:242-9.
5. Ritterhouse LL. Targeted RNA sequencing in non-small cell lung cancer. J Mol Diagn 2019;21:183-5.
6. Seto K, Masago K, Fujita S, et al. Targeted RNA sequencing with touch imprint cytology samples for non-small cell lung cancer patients. Thorac Cancer 2020;11:1827-34.
7. Heyer EE, Deveson IW, Wooi D, et al. Diagnosis of fusion genes using targeted RNA sequencing. Nat Commun 2019;10:1388.
8. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71.
9. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019;30:1121-6.
10. Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 2020;383:931-43.
11. Cohen D, Hondelink LM, Solleveld-Westerink N, et al. Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. J Thorac Oncol 2020;15:1000-14.
12. Li W, Wan R, Guo L, et al. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. BMC Med 2022;20:160.
13. Yang SR, Aypar U, Rosen EY, et al. A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res 2021;27:1316-28.
14. Xiang C, Guo L, Zhao R, et al. Identification and validation of noncanonical RET fusions in non-small-cell lung cancer through DNA and RNA sequencing. J Mol Diagn 2022;24:374-85.
15. Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry. J Clin Oncol 2021;39:2791-802.
16. Drilon A, Somwar R, Mangatt BP, et al. Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers. Cancer Discov 2018;8:686-95.
17. Strohmeier S, Brcic I, Popper H, Liegl-Atzwanger B, Lindenmann J, Brcic L. Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma. Sci Rep 2021;11:9785.
18. Kulda V, Polivka J, Svaton M, et al. Next generation sequencing analysis and its benefit for targeted therapy of lung adenocarcinoma. Cancer Genomics Proteomics 2023;20:404-11.
